<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-title>Critical Care</journal-title><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">16780598</article-id><article-id pub-id-type="pmc">1550956</article-id><article-id pub-id-type="publisher-id">cc4946</article-id><article-id pub-id-type="doi">10.1186/cc4946</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Shorr</surname><given-names>Andrew F</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>afshorr@dnamail.com</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Bernard</surname><given-names>Gordon R</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>gordon.bernard@vanderbilt.edu</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Dhainaut</surname><given-names>Jean-Francois</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>dhainaut@cochin.univ-paris5.fr</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Russell</surname><given-names>James R</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>jrussell@providencehealth.bc.ca</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Macias</surname><given-names>William L</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>wlm@lilly.com</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Nelson</surname><given-names>David R</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>nelsondr@lilly.com</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Sundin</surname><given-names>David P</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>sundindp@lilly.com</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Medicine, Section of Pulmonary and Critical Care Medicine, Washington Hospital Center, Washington, DC, USA</aff><aff id="I2"><label>2</label>Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University, Nashville, Tennessee, USA</aff><aff id="I3"><label>3</label>Department of Intensive Care and Emergency Medicine, Cochin-Port Royal University Hospital, Paris 5 René Descartes University, Paris, France</aff><aff id="I4"><label>4</label>Critical Care Research, St Paul's Hospital and University of British Columbia McDonald Research Laboratories, Vancouver, Canada</aff><aff id="I5"><label>5</label>Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, Indiana, USA</aff><pub-date pub-type="ppub"><year>2006</year></pub-date><pub-date pub-type="epub"><day>15</day><month>6</month><year>2006</year></pub-date><volume>10</volume><issue>3</issue><fpage>R92</fpage><lpage>R92</lpage><ext-link ext-link-type="uri" xlink:href="http://ccforum.com/content/10/3/R92"></ext-link><history><date date-type="received"><day>27</day><month>3</month><year>2006</year></date><date date-type="rev-request"><day>18</day><month>4</month><year>2006</year></date><date date-type="rev-recd"><day>23</day><month>4</month><year>2006</year></date><date date-type="accepted"><day>12</day><month>5</month><year>2006</year></date></history><permissions><copyright-statement>Copyright © 2006 Shorr et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2006</copyright-year><copyright-holder>Shorr et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"></ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title><offsets xml_i="4462" xml_f="4474" txt_i="11" txt_f="23">Introduction</offsets></title><p><offsets xml_i="4485" xml_f="4902" txt_i="24" txt_f="441">Protein C, because of its central role in hemostasis, plays an integral role in the host response to infection. Protein C depletion, resulting from increased consumption, degradation, and/or decreased synthesis, is characteristic of sepsis and has been shown to predict morbidity and mortality. The objective of this study was to determine whether early directional changes in protein C levels correlate with outcome.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="4943" xml_f="4950" txt_i="443" txt_f="450">Methods</offsets></title><p><offsets xml_i="4961" xml_f="5131" txt_i="451" txt_f="621">Patients in the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) clinical trial were assessed and categorized by baseline protein C (</offsets><italic><offsets xml_i="5139" xml_f="5141" txt_i="621" txt_f="623">n </offsets></italic><offsets xml_i="5150" xml_f="5262" txt_i="623" txt_f="735">= 1574). Deficiency was categorized as: severe deficiency, protein C levels ≤ 40% of normal protein C activity (</offsets><italic><offsets xml_i="5270" xml_f="5272" txt_i="735" txt_f="737">n </offsets></italic><offsets xml_i="5281" xml_f="5371" txt_i="737" txt_f="827">= 615, 39% of patients); deficient, protein C levels 41–80% of normal protein C activity (</offsets><italic><offsets xml_i="5379" xml_f="5381" txt_i="827" txt_f="829">n </offsets></italic><offsets xml_i="5390" xml_f="5467" txt_i="829" txt_f="903">= 764, 48.5% of patients); and normal, &gt;80% of normal protein C activity (</offsets><italic><offsets xml_i="5475" xml_f="5477" txt_i="903" txt_f="905">n </offsets></italic><offsets xml_i="5486" xml_f="5781" txt_i="905" txt_f="1200">= 195, 12.4% of patients). Logistic regression analysis of 28-day mortality for placebo patients was used to investigate whether baseline and day 1 protein C levels were independent risk factors for mortality. The impact of treatment with drotrecogin alfa (activated) (DrotAA) was also assessed.</offsets></p></sec><sec><title><offsets xml_i="5803" xml_f="5810" txt_i="1202" txt_f="1209">Results</offsets></title><p><offsets xml_i="5821" xml_f="6053" txt_i="1210" txt_f="1442">Protein C levels at baseline and day 1 were independent risk factors in placebo patients. If baseline protein C levels of severely deficient placebo patients remained ≤ 40% at day 1 their odds of death increased (odds ratio = 2.75, </offsets><italic><offsets xml_i="6061" xml_f="6063" txt_i="1442" txt_f="1444">P </offsets></italic><offsets xml_i="6072" xml_f="6181" txt_i="1444" txt_f="1547">&lt; 0.0001), while if levels improved to &gt;40% by day 1 their risk of death decreased (odds ratio = 0.43, </offsets><italic><offsets xml_i="6189" xml_f="6191" txt_i="1547" txt_f="1549">P </offsets></italic><offsets xml_i="6200" xml_f="6354" txt_i="1549" txt_f="1700">= 0.03). If baseline protein C levels of placebo patients were &gt;40% but decreased by ≥ 10% on day 1, their risk of death increased (odds ratio = 1.87, </offsets><italic><offsets xml_i="6362" xml_f="6364" txt_i="1700" txt_f="1702">P </offsets></italic><offsets xml_i="6373" xml_f="6457" txt_i="1702" txt_f="1786">= 0.02). DrotAA treatment improved protein C levels by day 1 compared with placebo (</offsets><italic><offsets xml_i="6465" xml_f="6467" txt_i="1786" txt_f="1788">P </offsets></italic><offsets xml_i="6476" xml_f="6792" txt_i="1788" txt_f="2101">= 0.008) and reduced the risk of death in severely deficient (≤ 40%) patients at baseline. Treatment also decreased the number of severely protein C deficient (= 40%) patients and decreased the number of deficient (41–80%) patients and normal (&gt;80%) patients who had a ≥ 10% decrease in protein C levels by day 1.</offsets></p></sec><sec><title><offsets xml_i="6814" xml_f="6824" txt_i="2103" txt_f="2113">Conclusion</offsets></title><p><offsets xml_i="6835" xml_f="7135" txt_i="2114" txt_f="2414">Baseline protein C levels were an independent predictor of sepsis outcome. Day 1 changes in protein C, regardless of baseline levels, were also predictive of outcome. The association of DrotAA treatment, increased protein C levels, and improved survival may partially explain the mechanism of action.</offsets></p></sec></abstract></article-meta></front><body><sec><title><offsets xml_i="7197" xml_f="7209" txt_i="2423" txt_f="2435">Introduction</offsets></title><p><offsets xml_i="7220" xml_f="7494" txt_i="2436" txt_f="2710">The protein C pathway, because of its central role in hemostasis, plays an integral role in the host response to infection. Activated protein C inactivates coagulation factors, enhances fibrinolysis, and at high concentrations reduces the release of inflammatory cytokines [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="7525" xml_f="7526" txt_i="2710" txt_f="2711">1</offsets></xref><offsets xml_i="7533" xml_f="7534" txt_i="2711" txt_f="2712">-</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="7565" xml_f="7566" txt_i="2712" txt_f="2713">6</offsets></xref><offsets xml_i="7573" xml_f="7811" txt_i="2713" txt_f="2951">]. Due to increased consumption, degradation, and/or decreased synthesis, protein C deficiency is characteristic of severe sepsis – with the onset of protein C deficiency probably occurring before clinical diagnosis of organ dysfunction [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="7842" xml_f="7843" txt_i="2951" txt_f="2952">7</offsets></xref><offsets xml_i="7850" xml_f="7851" txt_i="2952" txt_f="2953">-</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="7882" xml_f="7883" txt_i="2953" txt_f="2954">9</offsets></xref><offsets xml_i="7890" xml_f="8049" txt_i="2954" txt_f="3113">]. Numerous studies have demonstrated that decreased circulating levels of protein C in septic patients are associated with increased morbidity and mortality [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="8080" xml_f="8081" txt_i="3113" txt_f="3114">7</offsets></xref><offsets xml_i="8088" xml_f="8089" txt_i="3114" txt_f="3115">-</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="8121" xml_f="8123" txt_i="3115" txt_f="3117">11</offsets></xref><offsets xml_i="8130" xml_f="8280" txt_i="3117" txt_f="3267">]. The extent of protein C deficiency, assessed at the time of diagnosis, correlates with increased morbidity and mortality, but only as a threshold [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="8312" xml_f="8314" txt_i="3267" txt_f="3269">12</offsets></xref><offsets xml_i="8321" xml_f="8620" txt_i="3269" txt_f="3568">]; that is, only severe protein C deficiency (protein C levels ≤ 40% of normal protein C activity) correlates with decreased survival. Continued protein C deficiency or the development of protein C deficiency within approximately one day of diagnosis, however, has been correlated with early death [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="8652" xml_f="8654" txt_i="3568" txt_f="3570">12</offsets></xref><offsets xml_i="8661" xml_f="8663" txt_i="3570" txt_f="3572">].</offsets></p><p><offsets xml_i="8670" xml_f="8775" txt_i="3573" txt_f="3678">Drotrecogin alfa (activated) (DrotAA) has been shown to improve survival in patients with severe sepsis [</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="8807" xml_f="8809" txt_i="3678" txt_f="3680">13</offsets></xref><offsets xml_i="8816" xml_f="8852" txt_i="3680" txt_f="3716">] and to increase protein C levels [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="8884" xml_f="8886" txt_i="3716" txt_f="3718">14</offsets></xref><offsets xml_i="8893" xml_f="9096" txt_i="3718" txt_f="3921">]. This effect appears to be unique to protein C, as similar findings were not observed with protein S and antithrombin III. The treatment effect appeared independent of baseline protein C measurements [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="9128" xml_f="9130" txt_i="3921" txt_f="3923">15</offsets></xref><offsets xml_i="9137" xml_f="9149" txt_i="3923" txt_f="3935">], although </offsets><italic><offsets xml_i="9157" xml_f="9166" txt_i="3935" txt_f="3944">a priori </offsets></italic><offsets xml_i="9175" xml_f="9274" txt_i="3944" txt_f="4043">it was hypothesized that protein-C-deficient patients would derive the most benefit from treatment.</offsets></p><p><offsets xml_i="9281" xml_f="9946" txt_i="4044" txt_f="4709">We hypothesized that early (baseline to day 1) directional changes in protein C (naturally occurring or from DrotAA treatment) would correlate with outcome. Since lower protein C levels appear to correlate with worse outcomes, we explored whether the observed change from baseline in the first day (either an increase or decrease) would contribute meaningful additional information to baseline levels of protein C, with respect to predicting outcome. In addition, we explored whether treatment with DrotAA would reduce the number of patients with day 1 decreases in protein C levels or increase the number of patients that improved from severe protein C deficiency.</offsets></p></sec><sec sec-type="materials|methods"><title><offsets xml_i="9997" xml_f="10018" txt_i="4711" txt_f="4732">Materials and methods</offsets></title><sec><title><offsets xml_i="10038" xml_f="10046" txt_i="4733" txt_f="4741">Patients</offsets></title><p><offsets xml_i="10057" xml_f="10505" txt_i="4742" txt_f="5190">The Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial was conducted in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with good clinical practices and applicable laws and regulations. The trial design, patient disposition, inclusion/exclusion criteria, and results of the pivotal PROWESS clinical trial have been described in detail previously [</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="10537" xml_f="10539" txt_i="5190" txt_f="5192">13</offsets></xref><offsets xml_i="10546" xml_f="10677" txt_i="5192" txt_f="5323">]. Briefly, PROWESS was a multicountry (164 sites in 11 countries), randomized, placebo-controlled clinical trial of DrotAA (Xigris</offsets><sup><offsets xml_i="10682" xml_f="10683" txt_i="5323" txt_f="5324">®</offsets></sup><offsets xml_i="10689" xml_f="11121" txt_i="5324" txt_f="5756">; Eli Lilly and Company, Indianapolis, IN, USA) in adult patients with severe sepsis. All investigative sites obtained approval for the study from their institutional review boards. Written informed consent was obtained from all patients or their legal representatives. Although protein C activity levels were measured in the PROWESS trial, patients with missing baseline protein C activity values were excluded from these analyses.</offsets></p></sec><sec><title><offsets xml_i="11143" xml_f="11150" txt_i="5758" txt_f="5765">Samples</offsets></title><p><offsets xml_i="11161" xml_f="11410" txt_i="5766" txt_f="6015">In the PROWESS trial, plasma samples were obtained at baseline and daily through study day 7. A central laboratory (Covance Central Laboratory Services, Indianapolis, IN, USA) performed all assays. The protein C activity assay was performed on a STA</offsets><sup><offsets xml_i="11415" xml_f="11417" txt_i="6015" txt_f="6017">® </offsets></sup><offsets xml_i="11423" xml_f="11457" txt_i="6017" txt_f="6051">coagulation analyzer using the STA</offsets><sup><offsets xml_i="11462" xml_f="11463" txt_i="6051" txt_f="6052">®</offsets></sup><offsets xml_i="11469" xml_f="11477" txt_i="6052" txt_f="6060">-Staclot</offsets><sup><offsets xml_i="11482" xml_f="11484" txt_i="6060" txt_f="6062">® </offsets></sup><offsets xml_i="11490" xml_f="11647" txt_i="6062" txt_f="6219">Protein C kit (Diagnostica Stago, Asnieres-Sur-Seine, France), which has a coefficient of variation of 7.5%. Protein S measurements were performed on the STA</offsets><sup><offsets xml_i="11652" xml_f="11654" txt_i="6219" txt_f="6221">® </offsets></sup><offsets xml_i="11660" xml_f="11694" txt_i="6221" txt_f="6255">coagulation analyzer using the STA</offsets><sup><offsets xml_i="11699" xml_f="11700" txt_i="6255" txt_f="6256">®</offsets></sup><offsets xml_i="11706" xml_f="11714" txt_i="6256" txt_f="6264">-Staclot</offsets><sup><offsets xml_i="11719" xml_f="11721" txt_i="6264" txt_f="6266">® </offsets></sup><offsets xml_i="11727" xml_f="12007" txt_i="6266" txt_f="6542">Protein S kit (Diagnostica Stago). The antithrombin III activity was quantitated using a chromogenic activity assay (Stachrome ATIII; Diagnostica Stago). IL-6 antigen levels were measured by enzyme immunoassay (Quantikine Human IL-6 HS kit; R&amp;D Systems, Minneapolis, MN, USA).</offsets></p></sec><sec><title><offsets xml_i="12029" xml_f="12048" txt_i="6544" txt_f="6563">Statistical methods</offsets></title><p><offsets xml_i="12059" xml_f="12386" txt_i="6564" txt_f="6891">The relationship between baseline protein C levels and clinical variables was assessed with Spearman rank correlation when both variables were continuous, and was assessed with the Wilcoxon rank-sum test (for groups with two levels, for example comorbidities) when continuous protein C levels were compared between two classes.</offsets></p><p><offsets xml_i="12393" xml_f="12439" txt_i="6892" txt_f="6938">Protein C classes were defined prospectively [</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="12471" xml_f="12473" txt_i="6938" txt_f="6940">13</offsets></xref><offsets xml_i="12480" xml_f="12481" txt_i="6940" txt_f="6941">,</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="12513" xml_f="12515" txt_i="6941" txt_f="6943">15</offsets></xref><offsets xml_i="12522" xml_f="13108" txt_i="6943" txt_f="7526">] into normal (&gt;80% of normal protein C activity), deficient (41–80% of normal protein C activity), and severely deficient (≤ 40% of normal protein C activity). The protein C status was evaluated to determine whether it was a significant risk factor for mortality among PROWESS placebo patients. Multivariable logistic regression was used to adjust for six risk factors (Acute Physiology and Chronic Health Evaluation (APACHE) II score, age, baseline IL-6 level, presence of comorbidities, presence of any dependencies as determined by ability to conduct activities of daily living [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="13140" xml_f="13142" txt_i="7526" txt_f="7528">16</offsets></xref><offsets xml_i="13149" xml_f="13275" txt_i="7528" txt_f="7654">], and urosepsis) previously found to be significant predictors of outcome in analyses of data from PROWESS placebo patients [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="13307" xml_f="13309" txt_i="7654" txt_f="7656">15</offsets></xref><offsets xml_i="13316" xml_f="13737" txt_i="7656" txt_f="8077">]. Baseline protein C classes were initially included. Variables assessing protein C change from baseline were subsequently included in stepwise logistic regression. In some cases the moderately deficient protein C and normal protein C classes were combined for analysis of mortality by baseline protein C activity levels, after it was determined that there was no increased risk in the odds of death (odds ratio = 0.89, </offsets><italic><offsets xml_i="13745" xml_f="13747" txt_i="8077" txt_f="8079">P </offsets></italic><offsets xml_i="13756" xml_f="13863" txt_i="8079" txt_f="8183">= 0.07, comparing 41–80% of normal protein C activity with &gt;80% of normal protein C activity; see Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="13895" xml_f="13896" txt_i="8183" txt_f="8184">2</offsets></xref><offsets xml_i="13903" xml_f="13935" txt_i="8184" txt_f="8216">), over the time frame analyzed.</offsets></p><p><offsets xml_i="13942" xml_f="14367" txt_i="8217" txt_f="8642">For patients with both baseline and day 1 protein C measurements, treatment differences of antithrombin, IL-6, and protein S levels at baseline and day 1, and their changes, were compared with Wilcoxon rank-sum tests. Survival patterns were illustrated with Kaplan-Meier estimates and were compared using log-rank tests. Statistical analyses were performed using SAS version 8.02 software (SAS Institute Inc., Cary, NC, USA).</offsets></p></sec></sec><sec><title><offsets xml_i="14395" xml_f="14402" txt_i="8645" txt_f="8652">Results</offsets></title><p><offsets xml_i="14413" xml_f="15029" txt_i="8653" txt_f="9269">The PROWESS trial enrolled 1690 patients, of which 850 received DrotAA and 840 received placebo. Baseline protein C measurements were obtained for 1574 patients (799 receiving DrotAA and 775 receiving placebo). Patients who had missing baseline protein C values did not significantly differ from the overall population in baseline characteristics, disease severity measures, or outcomes (data not shown). Values ranged from 5% to 200% of normal, with an average of 50.6 ± 26.7% (mean ± standard deviation). Using prospectively defined criteria, patients were classified as either severely deficient (≤ 40% activity, </offsets><italic><offsets xml_i="15037" xml_f="15039" txt_i="9269" txt_f="9271">n </offsets></italic><offsets xml_i="15048" xml_f="15103" txt_i="9271" txt_f="9326">= 615, 39.1% of patients), deficient (41–80% activity, </offsets><italic><offsets xml_i="15111" xml_f="15113" txt_i="9326" txt_f="9328">n </offsets></italic><offsets xml_i="15122" xml_f="15178" txt_i="9328" txt_f="9381">= 764, 48.5% of patients), or normal (&gt;80% activity, </offsets><italic><offsets xml_i="15186" xml_f="15188" txt_i="9381" txt_f="9383">n </offsets></italic><offsets xml_i="15197" xml_f="15432" txt_i="9383" txt_f="9618">= 195, 12.4% of patients). It should be emphasized that the levels of protein C reported relate to levels of endogenous inactivated protein C. In addition, the reported protein C values do not reflect intravenously administered DrotAA.</offsets></p><sec><title><offsets xml_i="15448" xml_f="15557" txt_i="9619" txt_f="9728">Relationship between baseline protein C class, clinical and demographic characteristics, and 28-day mortality</offsets></title><p><offsets xml_i="15568" xml_f="15574" txt_i="9729" txt_f="9735">Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="15606" xml_f="15607" txt_i="9735" txt_f="9736">1</offsets></xref><offsets xml_i="15614" xml_f="15954" txt_i="9736" txt_f="10076"> presents seven baseline characteristics of PROWESS patients as they relate to baseline protein C class and treatment group. Six of the baseline characteristics (APACHE II score, age, log IL-6, presence of comorbidities, presence of dependencies, and urosepsis) have previously been shown to predict outcome among PROWESS placebo patients [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="15986" xml_f="15988" txt_i="10076" txt_f="10078">15</offsets></xref><offsets xml_i="15995" xml_f="16064" txt_i="10078" txt_f="10147">] and were specifically chosen to present for that reason (see Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="16096" xml_f="16097" txt_i="10147" txt_f="10148">2</offsets></xref><offsets xml_i="16104" xml_f="16214" txt_i="10148" txt_f="10258">). Significant correlations were observed across baseline protein C classes for the APACHE II score and IL-6 (</offsets><italic><offsets xml_i="16222" xml_f="16224" txt_i="10258" txt_f="10260">P </offsets></italic><offsets xml_i="16233" xml_f="16373" txt_i="10260" txt_f="10397">&lt; 0.0001 for both). Comorbidities, dependencies, and septic shock also had a significant association with baseline protein C levels (all </offsets><italic><offsets xml_i="16381" xml_f="16383" txt_i="10397" txt_f="10399">P </offsets></italic><offsets xml_i="16392" xml_f="16582" txt_i="10399" txt_f="10589">≤ 0.007). The 28-day mortality among the PROWESS placebo patients was significantly higher in the severely deficient (≤ 40% activity) protein C group than in the deficient (41–80% activity, </offsets><italic><offsets xml_i="16590" xml_f="16592" txt_i="10589" txt_f="10591">P </offsets></italic><offsets xml_i="16601" xml_f="16644" txt_i="10591" txt_f="10628">&lt; 0.0001) and normal (&gt;80% activity, </offsets><italic><offsets xml_i="16652" xml_f="16654" txt_i="10628" txt_f="10630">P </offsets></italic><offsets xml_i="16663" xml_f="16778" txt_i="10630" txt_f="10745">= 0.006) protein C groups. The deficient and normal groups, however, did not differ significantly from each other (</offsets><italic><offsets xml_i="16786" xml_f="16788" txt_i="10745" txt_f="10747">P </offsets></italic><offsets xml_i="16797" xml_f="16805" txt_i="10747" txt_f="10755">= 0.71).</offsets></p></sec><sec><title><offsets xml_i="16827" xml_f="16919" txt_i="10757" txt_f="10849">Baseline and day 1 changes in protein C levels predict mortality in PROWESS placebo patients</offsets></title><p><offsets xml_i="16930" xml_f="17197" txt_i="10850" txt_f="11117">To determine whether low or decreasing protein C places patients at a high risk of mortality, analyses adjusting for six previously defined significant risk factors (APACHE II score, age, log IL-6, presence of comorbidities, presence of dependencies, and urosepsis) [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="17229" xml_f="17231" txt_i="11117" txt_f="11119">15</offsets></xref><offsets xml_i="17238" xml_f="17300" txt_i="11119" txt_f="11181">] were performed on data from PROWESS placebo patients (Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="17332" xml_f="17333" txt_i="11181" txt_f="11182">2</offsets></xref><offsets xml_i="17340" xml_f="17483" txt_i="11182" txt_f="11325">). Baseline severe protein C deficiency (≤ 40% activity) was associated with a significantly higher risk of death (adjusted odds ratio = 1.75, </offsets><italic><offsets xml_i="17491" xml_f="17493" txt_i="11325" txt_f="11327">P </offsets></italic><offsets xml_i="17502" xml_f="17612" txt_i="11327" txt_f="11434">= 0.003) than those patients without severe deficiency (baseline protein C level 41–80% and &gt;80% activity).</offsets></p><p><offsets xml_i="17619" xml_f="17726" txt_i="11435" txt_f="11542">Changes in protein C activity level in the first day also significantly predicted the risk of death (Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="17758" xml_f="17759" txt_i="11542" txt_f="11543">2</offsets></xref><offsets xml_i="17766" xml_f="17939" txt_i="11543" txt_f="11716">). If placebo patients were severely deficient at baseline and remained severely deficient on day 1, their odds of death were 2.74 times higher than other placebo patients (</offsets><italic><offsets xml_i="17947" xml_f="17949" txt_i="11716" txt_f="11718">P </offsets></italic><offsets xml_i="17958" xml_f="18122" txt_i="11718" txt_f="11873">&lt; 0.0001). Placebo patients with deficient (41–80%) and normal (&gt;80%) protein C activity levels at baseline (for example, baseline protein C &gt;40% in Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="18154" xml_f="18155" txt_i="11873" txt_f="11874">2</offsets></xref><offsets xml_i="18162" xml_f="18287" txt_i="11874" txt_f="11999">) who had a ≥ 10% decrease in protein C levels on day 1 also had a significantly increased risk of death (odds ratio = 1.87, </offsets><italic><offsets xml_i="18295" xml_f="18297" txt_i="11999" txt_f="12001">P </offsets></italic><offsets xml_i="18306" xml_f="18628" txt_i="12001" txt_f="12320">= 0.02), compared with patients who did not have a decrease of this magnitude. If placebo patients were severely deficient (≤ 40%) at baseline but improved to &gt;40% activity by day 1, their risk of death was significantly reduced compared with patients whose protein C activity levels remained ≤ 40% (odds ratio = 0.43, </offsets><italic><offsets xml_i="18636" xml_f="18638" txt_i="12320" txt_f="12322">P </offsets></italic><offsets xml_i="18647" xml_f="19071" txt_i="12322" txt_f="12740">= 0.03). Other variables associated with change did not enter the model. For instance, no significant increased risk was observed for day 1 protein C decreases in the severely deficient subgroup (≤ 40% activity). In contrast, no significant decreased risks were observed for day 1 protein C increases in the deficient (41–80% activity) and normal (&gt;80% activity) subgroups (for example, baseline levels &gt;40% activity).</offsets></p><p><offsets xml_i="19078" xml_f="19265" txt_i="12741" txt_f="12928">To illustrate the significance observed in day 1 protein C changes, the PROWESS placebo mortality rates, based on baseline levels and first day protein C changes, are presented in Figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="19295" xml_f="19296" txt_i="12928" txt_f="12929">1</offsets></xref><offsets xml_i="19303" xml_f="19356" txt_i="12929" txt_f="12982">. Of the severely deficient placebo patients (Figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="19386" xml_f="19387" txt_i="12982" txt_f="12983">1</offsets></xref><offsets xml_i="19394" xml_f="19786" txt_i="12983" txt_f="13375">, left-hand bar graphs), 7.4% did not survive to day 1 for a second protein C measure (area above the dotted line). After removing patients who died before the day 1 protein C measurement was taken (dotted line), the mortality of severely deficient patients at baseline (34.9%) increased to 40.7% if their protein C levels remained ≤ 40% and decreased to 24.5% if their levels rose above 40%.</offsets></p><p><offsets xml_i="19793" xml_f="19835" txt_i="13376" txt_f="13418">In the middle set of bar graphs in Figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="19865" xml_f="19866" txt_i="13418" txt_f="13419">1</offsets></xref><offsets xml_i="19873" xml_f="20268" txt_i="13419" txt_f="13814">, 1.0% of moderately deficient placebo patients died before a second measure could be taken (area above dotted line). After removing patients who died before a day 1 protein C measurement was taken (dotted line), the mortality of deficient patients at baseline (24.0%) increased to 31.1% if there was ≥ 10% decrease in their protein C levels and decreased to 21.0% if no decrease ≥ 10% occurred.</offsets></p><p><offsets xml_i="20275" xml_f="20330" txt_i="13815" txt_f="13870">Finally, in the right-hand set of bar graphs in Figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="20360" xml_f="20361" txt_i="13870" txt_f="13871">1</offsets></xref><offsets xml_i="20368" xml_f="20813" txt_i="13871" txt_f="14316">, 1.0% of placebo patients with normal protein C levels died before a second measure could be taken (area above dotted line). After removing patients who died before a day 1 protein C measurement was taken (dotted line), the mortality of patients with normal protein C levels at baseline (26.0%) increased if there was a decrease in their protein C levels ≥ 10% (36.7%) and decreased if there was no drop in their protein C levels ≥ 10% (20.6%).</offsets></p></sec><sec><title><offsets xml_i="20835" xml_f="20890" txt_i="14318" txt_f="14373">Day 1 improvement of protein C levels: effect of DrotAA</offsets></title><p><offsets xml_i="20901" xml_f="21024" txt_i="14374" txt_f="14497">Although randomization in the PROWESS trial created a placebo group with slightly higher median baseline protein C levels (</offsets><italic><offsets xml_i="21032" xml_f="21034" txt_i="14497" txt_f="14499">P </offsets></italic><offsets xml_i="21043" xml_f="21057" txt_i="14499" txt_f="14513">= 0.06, Table </offsets><xref ref-type="table" rid="T3"><offsets xml_i="21089" xml_f="21090" txt_i="14513" txt_f="14514">3</offsets></xref><offsets xml_i="21097" xml_f="21180" txt_i="14514" txt_f="14597">), by day 1, DrotAA-treated patients had significantly increased protein C levels (</offsets><italic><offsets xml_i="21188" xml_f="21190" txt_i="14597" txt_f="14599">P </offsets></italic><offsets xml_i="21199" xml_f="21335" txt_i="14599" txt_f="14735">= 0.008). The median day 1 change in protein C showed a 6% increase for DrotAA-treated patients, compared with a 0% change for placebo (</offsets><italic><offsets xml_i="21343" xml_f="21345" txt_i="14735" txt_f="14737">P </offsets></italic><offsets xml_i="21354" xml_f="21367" txt_i="14737" txt_f="14747">&lt; 0.0001).</offsets></p><p><offsets xml_i="21374" xml_f="21380" txt_i="14748" txt_f="14754">Table </offsets><xref ref-type="table" rid="T4"><offsets xml_i="21412" xml_f="21413" txt_i="14754" txt_f="14755">4</offsets></xref><offsets xml_i="21420" xml_f="21617" txt_i="14755" txt_f="14952"> demonstrates the specificity of the DrotAA effect. There was no significant difference between treatment groups in day 1 levels or the day 1 change in two other markers of coagulation, protein S (</offsets><italic><offsets xml_i="21625" xml_f="21627" txt_i="14952" txt_f="14954">P </offsets></italic><offsets xml_i="21636" xml_f="21647" txt_i="14954" txt_f="14965">= 0.41 and </offsets><italic><offsets xml_i="21655" xml_f="21657" txt_i="14965" txt_f="14967">P </offsets></italic><offsets xml_i="21666" xml_f="21710" txt_i="14967" txt_f="15011">= 0.59, respectively) and antithrombin III (</offsets><italic><offsets xml_i="21718" xml_f="21720" txt_i="15011" txt_f="15013">P </offsets></italic><offsets xml_i="21729" xml_f="21740" txt_i="15013" txt_f="15024">= 0.61 and </offsets><italic><offsets xml_i="21748" xml_f="21750" txt_i="15024" txt_f="15026">P </offsets></italic><offsets xml_i="21759" xml_f="21905" txt_i="15026" txt_f="15172">= 0.88, respectively). Although there was no significant difference between treatment groups in the day 1 levels of the inflammation marker IL-6 (</offsets><italic><offsets xml_i="21913" xml_f="21915" txt_i="15172" txt_f="15174">P </offsets></italic><offsets xml_i="21924" xml_f="22005" txt_i="15174" txt_f="15255">= 0.44), the day 1 change in IL-6 was significantly reduced in the DrotAA group (</offsets><italic><offsets xml_i="22013" xml_f="22015" txt_i="15255" txt_f="15257">P </offsets></italic><offsets xml_i="22024" xml_f="22118" txt_i="15257" txt_f="15351">= 0.006). There was a slight imbalance of higher IL-6 levels in the DrotAA group at baseline (</offsets><italic><offsets xml_i="22126" xml_f="22128" txt_i="15351" txt_f="15353">P </offsets></italic><offsets xml_i="22137" xml_f="22145" txt_i="15353" txt_f="15361">= 0.08).</offsets></p><p><offsets xml_i="22152" xml_f="22323" txt_i="15362" txt_f="15533">The proportion of PROWESS patients in each baseline protein C category that improved or worsened by day 1 with DrotAA treatment is illustrated in the bottom half of Table </offsets><xref ref-type="table" rid="T3"><offsets xml_i="22355" xml_f="22356" txt_i="15533" txt_f="15534">3</offsets></xref><offsets xml_i="22363" xml_f="22538" txt_i="15534" txt_f="15706">. DrotAA significantly increased the proportion of severely deficient patients whose protein C levels improved to deficient or normal levels (that is to say &gt;40% activity, </offsets><italic><offsets xml_i="22546" xml_f="22548" txt_i="15706" txt_f="15708">P </offsets></italic><offsets xml_i="22557" xml_f="22687" txt_i="15708" txt_f="15835">&lt; 0.0001). In addition, DrotAA significantly decreased the proportion of deficient patients who had a ≥ 10% drop in protein C (</offsets><italic><offsets xml_i="22695" xml_f="22697" txt_i="15835" txt_f="15837">P </offsets></italic><offsets xml_i="22706" xml_f="22809" txt_i="15837" txt_f="15940">= 0.0002) and numerically reduced the proportion of normal patients who had a ≥ 10% drop in protein C (</offsets><italic><offsets xml_i="22817" xml_f="22819" txt_i="15940" txt_f="15942">P </offsets></italic><offsets xml_i="22828" xml_f="22836" txt_i="15942" txt_f="15950">= 0.09).</offsets></p><p><offsets xml_i="22843" xml_f="23032" txt_i="15951" txt_f="16140">Survival curves (Kaplan-Meier estimates) of PROWESS placebo and DrotAA-treated patients, based on baseline protein C class and the day 1 change in protein C levels, are presented in Figure </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="23062" xml_f="23063" txt_i="16140" txt_f="16141">2</offsets></xref><offsets xml_i="23070" xml_f="23107" txt_i="16141" txt_f="16178">. Curves of placebo patients (Figure </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="23137" xml_f="23139" txt_i="16178" txt_f="16180">2a</offsets></xref><offsets xml_i="23146" xml_f="23614" txt_i="16180" txt_f="16642">) who were severely deficient (≤ 40%) and deficient (41–80%) at baseline were significantly better in patients whose day 1 protein C levels improved to &gt;40% or stabilized (no decrease ≥ 10%) than those whose day 1 protein C values remained ≤ 40% or had a ≥ 10% decrease. In the relatively small subgroup of patients with normal (&gt;80%) baseline protein C, the same trend was observed. In general, this same pattern was observed in DrotAA-treated patients (Figure </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="23644" xml_f="23646" txt_i="16642" txt_f="16644">2b</offsets></xref><offsets xml_i="23653" xml_f="23792" txt_i="16644" txt_f="16780">), although the degree of increase in mortality of patients with normal (&gt;80%) baseline protein C and a ≥ 10% decrease was not observed.</offsets></p></sec></sec><sec><title><offsets xml_i="23820" xml_f="23830" txt_i="16783" txt_f="16793">Discussion</offsets></title><p><offsets xml_i="23841" xml_f="24628" txt_i="16794" txt_f="17581">This analysis demonstrates that the directional change of protein C levels correlates with outcome and the change from baseline in the first day provides more information on the eventual prognosis than do baseline protein C levels alone in individuals with severe sepsis. Additionally, the risk for death associated with various protein C levels seems to follow a threshold effect with clear risk classes. Furthermore, early changes in protein C levels, in combination with baseline protein C levels, predict outcome. Patients whose protein C levels fail to stabilize (deficient patients and normal patients) or fail to improve (severely deficient patients) faced a higher risk of death. Finally, DrotAA appears to alter survival through its direct impact on endogenous protein C levels.</offsets></p><p><offsets xml_i="24635" xml_f="24769" txt_i="17582" txt_f="17716">The current study differs from and builds on a previous study investigating the interaction of protein C levels and DrotAA treatment [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="24801" xml_f="24803" txt_i="17716" txt_f="17718">15</offsets></xref><offsets xml_i="24810" xml_f="25514" txt_i="17718" txt_f="18419">]. For that past assessment, all protein-C-deficient patients were pooled into a common group and no effort was made to separate the moderately and severely deficient protein C classes. In the present analysis, risk for mortality was not continuous within the deficient group. The likelihood of death was very high in severely deficient protein C patients (protein C levels ≤ 40% of normal), while the risk of death in patients with deficient (41–80% of normal) and normal (&gt;80% of normal) protein C levels was equivalent. It is possible, however, that the risk of death in moderately deficient and normal protein C groups would not be the same if protein C was analyzed over a greater period of time.</offsets></p><p><offsets xml_i="25521" xml_f="25799" txt_i="18420" txt_f="18695">Our observation that mortality increased if baseline protein C levels were &gt;40% and if a patient's day 1 protein C levels fell by ≥ 10% is novel. These results are consistent with previous studies that suggested decreases in protein C levels precede overt clinical symptoms [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="25830" xml_f="25831" txt_i="18695" txt_f="18696">7</offsets></xref><offsets xml_i="25838" xml_f="25839" txt_i="18696" txt_f="18697">-</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="25870" xml_f="25871" txt_i="18697" txt_f="18698">9</offsets></xref><offsets xml_i="25878" xml_f="25926" txt_i="18698" txt_f="18746">] and may be predictive of increased mortality [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="25957" xml_f="25958" txt_i="18746" txt_f="18747">7</offsets></xref><offsets xml_i="25965" xml_f="25966" txt_i="18747" txt_f="18748">-</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="25998" xml_f="26000" txt_i="18748" txt_f="18750">11</offsets></xref><offsets xml_i="26007" xml_f="26483" txt_i="18750" txt_f="19226">]. Hence, future investigations should focus on measuring protein C levels as soon as possible after sepsis is suspected and then evaluate the role for serial protein C measurements. This could potentially provide a more rapid and accurate assessment of the patient's status. If such studies confirm that specific rapid declines in protein C levels can be readily detected, and further that they precede clinical deterioration, this information could be used to guide therapy.</offsets></p><p><offsets xml_i="26490" xml_f="27087" txt_i="19227" txt_f="19824">Results from this study also suggested that improvements in outcome hinge on increases in protein C levels over the first day following diagnosis and baseline protein C measurement. These improvements were observed to occur in patients not treated with DrotAA and could be a component of the natural host response or a result of the numerous currently available clinical interventions such as infection source control, antibiotics or other measures. On the other hand, the results presented here provide supportive evidence that DrotAA treatment specifically increases endogenous protein C levels.</offsets></p><p><offsets xml_i="27094" xml_f="28258" txt_i="19825" txt_f="20989">Regardless of the reason for improvement, the change from baseline data to day 1 data emphasized that it is important for these changes to occur rapidly. If protein C levels decrease by as little as 10% on day 1, mortality increases significantly among most individuals. Moreover, DrotAA treatment significantly reduces mortality in the severely deficient protein C group, probably reflecting these patients being more likely to have increased protein C levels at day 1 because of treatment with DrotAA. Conversely, DrotAA-treated patients with moderately deficient (41–80% of normal) or normal (80% of normal) protein C levels at baseline were less likely to have a ≥ 10% drop in protein C levels. This fact probably explains that the treatment effect of DrotAA is less robust in these populations. In lower risk patients DrotAA prevented the progression of low-risk individuals to high-risk status, presumably by stabilizing protein C levels. This apparent association between DrotAA treatment, increased protein C levels, and improved survival may suggest that the mechanism of action for DrotAA is primarily reflective of its direct impact on protein C levels.</offsets></p><p><offsets xml_i="28265" xml_f="28576" txt_i="20990" txt_f="21301">The relationship between protein C and DrotAA appears unique. For example, the increase in protein C levels with DrotAA treatment was not observed in a different anticoagulant (antithrombin III), although derangements in other coagulation markers have been previously observed to improve with DrotAA treatment [</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="28608" xml_f="28610" txt_i="21301" txt_f="21303">13</offsets></xref><offsets xml_i="28617" xml_f="28618" txt_i="21303" txt_f="21304">,</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="28650" xml_f="28652" txt_i="21304" txt_f="21306">14</offsets></xref><offsets xml_i="28659" xml_f="29322" txt_i="21306" txt_f="21969">]. The significant reduction from baseline levels of IL-6 could be from the anti-inflammatory activity of protein C, which stems from its antithrombotic activity or from a yet to be described mechanism. The potential insight gained by incorporation of dynamic assessments of protein C reinforces the plausibility of why DrotAA is efficacious in severe sepsis. Additional prospective studies looking at more rapid diagnosis of sepsis, early and serial assessment of individual changes in protein C levels, titration of DrotAA dose, and duration of DrotAA treatment using serial protein C assessment are clearly needed to further clarify the results presented here.</offsets></p><p><offsets xml_i="29329" xml_f="29968" txt_i="21970" txt_f="22609">There are important limitations to the present study. As a result of the exclusion criteria (patients at high risk of bleeding, patients with low platelet count, and so on), the actual prevalence of patients with low protein C levels in severe sepsis may be higher than observed in this study. Likewise, although many of the parameters assessed in this study were prospectively defined, most of the analyses in this study were performed in a retrospective manner. Finally, limitations in the availability of samples (patients with missing baseline protein C values) prevented a more robust analysis of the early daily changes in protein C.</offsets></p></sec><sec><title><offsets xml_i="29990" xml_f="30000" txt_i="22611" txt_f="22621">Conclusion</offsets></title><p><offsets xml_i="30011" xml_f="30650" txt_i="22622" txt_f="23261">In summary, the current study confirmed that baseline protein C levels are an independent predictor of outcome in severe sepsis patients. Early changes in protein C levels (such as day 1) were also significant risk factors in combination with baseline protein C levels. The risk associated with protein C levels appears to be categorical rather than continuous in nature. The data imply that DrotAA treatment decreases mortality in two ways: by raising protein C levels above 40% of the normal threshold, and by reducing the number of moderately deficient patients and normal patients who had a decrease in their baseline protein C levels </offsets></p></sec><sec><title><offsets xml_i="30672" xml_f="30684" txt_i="23263" txt_f="23275">Key messages</offsets></title><p><offsets xml_i="30695" xml_f="30823" txt_i="23276" txt_f="23404">• 	A decline in protein C levels in patients with severe sepsis and septic shock identifies a population at high risk for death.</offsets></p><p><offsets xml_i="30830" xml_f="30971" txt_i="23405" txt_f="23546">• 	Dynamic, temporal analysis of changes in protein C levels provides more insight into probable outcomes than a static, one-time assessment.</offsets></p><p><offsets xml_i="30978" xml_f="31100" txt_i="23547" txt_f="23669">• 	The risk for death associated with various protein C levels seems to follow a threshold effect with clear risk classes.</offsets></p><p><offsets xml_i="31107" xml_f="31237" txt_i="23670" txt_f="23800">• 	Drotrecogin alfa (activated) appears to exert its effect on mortality reduction in part through increasing levels of protein C.</offsets></p></sec><sec><title><offsets xml_i="31259" xml_f="31272" txt_i="23802" txt_f="23815">Abbreviations</offsets></title><p><offsets xml_i="31283" xml_f="31483" txt_i="23816" txt_f="24016">APACHE = Acute Physiology and Chronic Health Evaluation; DrotAA = drotrecogin alfa (activated); IL = interleukin; PROWESS = Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis.</offsets></p></sec><sec><title><offsets xml_i="31505" xml_f="31524" txt_i="24018" txt_f="24037">Competing interests</offsets></title><p><offsets xml_i="31535" xml_f="31823" txt_i="24038" txt_f="24326">Eli Lilly and Company provided support for this study. GRB, J-FD, JRR, and AFS have all participated in Eli Lilly and Company-sponsored clinical trials, and have all served as consultants for Eli Lilly and Company. WLM, DRN, and DP are employees and stockholders of Eli Lilly and Company.</offsets></p></sec><sec><title><offsets xml_i="31845" xml_f="31867" txt_i="24328" txt_f="24350">Authors' contributions</offsets></title><p><offsets xml_i="31878" xml_f="32288" txt_i="24351" txt_f="24761">WLM, DRN, GRB, DPS, and AFS participated in the conception and design of the study. GRB, J-FD, and JRR participated in the PROWESS clinical trial and contributed to data collection. All authors contributed to development and conduct of the principal analyses and participated in drafting the manuscript. All authors contributed to revision of the manuscript. All authors read and approved the final manuscript.</offsets></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>The authors would like to acknowledge the efforts of all the investigators, study coordinators, and pharmacists who were involved in the PROWESS clinical trial. Without their original efforts, this study would not have been possible. In addition, they would like to acknowledge Hangtao Xu and Chuyun Huang for their statistical support. Finally, the authors would especially like to acknowledge Nancy Correll for her detailed knowledge of the trial and her helpful discussions and suggestions for the manuscript.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Esmon</surname><given-names>CT</given-names></name></person-group><article-title>The protein C pathway</article-title><source>Chest</source><year>2003</year><volume>124</volume><issue>3 Suppl</issue><fpage>26S</fpage><lpage>32S</lpage><pub-id pub-id-type="pmid">12970121</pub-id><pub-id pub-id-type="doi">10.1378/chest.124.3_suppl.26S</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grinnell</surname><given-names>BW</given-names></name><name><surname>Hermann</surname><given-names>RB</given-names></name><name><surname>Yan</surname><given-names>SB</given-names></name></person-group><article-title>Human protein C inhibits selectin-mediated cell adhesion: role of unique fucosylated oligosaccharide</article-title><source>Glycobiology</source><year>1994</year><volume>4</volume><fpage>221</fpage><lpage>225</lpage><pub-id pub-id-type="pmid">7519910</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murakami</surname><given-names>K</given-names></name><name><surname>Okajima</surname><given-names>K</given-names></name><name><surname>Uchiba</surname><given-names>M</given-names></name><name><surname>Johno</surname><given-names>M</given-names></name><name><surname>Nakagaki</surname><given-names>T</given-names></name><name><surname>Okabe</surname><given-names>H</given-names></name><name><surname>Takatsuki</surname><given-names>K</given-names></name></person-group><article-title>Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production</article-title><source>Am J Physiol</source><year>1997</year><volume>272</volume><fpage>L197</fpage><lpage>L202</lpage><pub-id pub-id-type="pmid">9124369</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sakata</surname><given-names>Y</given-names></name><name><surname>Loskutoff</surname><given-names>DJ</given-names></name><name><surname>Gladson</surname><given-names>CL</given-names></name><name><surname>Hekman</surname><given-names>CM</given-names></name><name><surname>Griffin</surname><given-names>JH</given-names></name></person-group><article-title>Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor</article-title><source>Blood</source><year>1986</year><volume>68</volume><fpage>1218</fpage><lpage>1223</lpage><pub-id pub-id-type="pmid">3096399</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmidt-Supprian</surname><given-names>M</given-names></name><name><surname>Murphy</surname><given-names>C</given-names></name><name><surname>While</surname><given-names>B</given-names></name><name><surname>Lawler</surname><given-names>M</given-names></name><name><surname>Kapurniotu</surname><given-names>A</given-names></name><name><surname>Voelter</surname><given-names>W</given-names></name><name><surname>Smith</surname><given-names>O</given-names></name><name><surname>Bernhagen</surname><given-names>J</given-names></name></person-group><article-title>Activated protein C inhibits tumor necrosis factor and macrophage migration inhibitory factor production in monocytes</article-title><source>Eur Cytokine Netw</source><year>2000</year><volume>11</volume><fpage>407</fpage><lpage>413</lpage><pub-id pub-id-type="pmid">11022125</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shua</surname><given-names>F</given-names></name><name><surname>Kobayashia</surname><given-names>H</given-names></name><name><surname>Fukudomeb</surname><given-names>K</given-names></name><name><surname>Tsuneyoshib</surname><given-names>N</given-names></name><name><surname>Kimotob</surname><given-names>M</given-names></name><name><surname>Teraoa</surname><given-names>T</given-names></name></person-group><article-title>Activated protein C suppresses tissue factor expression on U937 cells in the endothelial protein C receptor-dependent manner</article-title><source>FEBS Lett</source><year>2000</year><volume>477</volume><fpage>208</fpage><lpage>212</lpage><pub-id pub-id-type="pmid">10908722</pub-id><pub-id pub-id-type="doi">10.1016/S0014-5793(00)01740-3</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fourrier</surname><given-names>F</given-names></name><name><surname>Chopin</surname><given-names>C</given-names></name><name><surname>Goudemand</surname><given-names>J</given-names></name><name><surname>Hendrycx</surname><given-names>S</given-names></name><name><surname>Caron</surname><given-names>C</given-names></name><name><surname>Rime</surname><given-names>A</given-names></name><name><surname>Marey</surname><given-names>A</given-names></name><name><surname>Lestavel</surname><given-names>P</given-names></name></person-group><article-title>Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies [see comment]</article-title><source>Chest</source><year>1992</year><volume>101</volume><fpage>816</fpage><lpage>823</lpage><pub-id pub-id-type="pmid">1531791</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mesters</surname><given-names>RM</given-names></name><name><surname>Helterbrand</surname><given-names>J</given-names></name><name><surname>Utterback</surname><given-names>BG</given-names></name><name><surname>Yan</surname><given-names>B</given-names></name><name><surname>Chao</surname><given-names>YB</given-names></name><name><surname>Fernandez</surname><given-names>JA</given-names></name><name><surname>Griffin</surname><given-names>JH</given-names></name><name><surname>Hartman</surname><given-names>DL</given-names></name></person-group><article-title>Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications</article-title><source>Crit Care Med</source><year>2000</year><volume>28</volume><fpage>2209</fpage><lpage>2216</lpage><pub-id pub-id-type="pmid">10921542</pub-id><pub-id pub-id-type="doi">10.1097/00003246-200007000-00005</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>SB</given-names></name><name><surname>Helterbrand</surname><given-names>JD</given-names></name><name><surname>Hartman</surname><given-names>DL</given-names></name><name><surname>Wright</surname><given-names>TJ</given-names></name><name><surname>Bernard</surname><given-names>GR</given-names></name></person-group><article-title>Low levels of protein C are associated with poor outcome in severe sepsis</article-title><source>Chest</source><year>2001</year><volume>120</volume><fpage>915</fpage><lpage>922</lpage><pub-id pub-id-type="pmid">11555529</pub-id><pub-id pub-id-type="doi">10.1378/chest.120.3.915</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fijnvandraat</surname><given-names>K</given-names></name><name><surname>Derkx</surname><given-names>B</given-names></name><name><surname>Peters</surname><given-names>M</given-names></name><name><surname>Bijlmer</surname><given-names>R</given-names></name><name><surname>Sturk</surname><given-names>A</given-names></name><name><surname>Prins</surname><given-names>MH</given-names></name><name><surname>van Deventer</surname><given-names>SJ</given-names></name><name><surname>ten Cate</surname><given-names>JW</given-names></name></person-group><article-title>Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality</article-title><source>Thromb Haemost</source><year>1995</year><volume>73</volume><fpage>15</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">7740486</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lorente</surname><given-names>JA</given-names></name><name><surname>Garcia-Frade</surname><given-names>LJ</given-names></name><name><surname>Landin</surname><given-names>L</given-names></name><name><surname>de Pablo</surname><given-names>R</given-names></name><name><surname>Torrado</surname><given-names>C</given-names></name><name><surname>Renes</surname><given-names>E</given-names></name><name><surname>Garcia-Avello</surname><given-names>A</given-names></name></person-group><article-title>Time course of hemostatic abnormalities in sepsis and its relation to outcome</article-title><source>Chest</source><year>1993</year><volume>103</volume><fpage>1536</fpage><lpage>1542</lpage><pub-id pub-id-type="pmid">8486040</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Macias</surname><given-names>WL</given-names></name><name><surname>Nelson</surname><given-names>DR</given-names></name></person-group><article-title>Severe protein C deficiency predicts early death in severe sepsis</article-title><source>Crit Care Med</source><year>2004</year><volume>32</volume><issue>5 Suppl</issue><fpage>S223</fpage><lpage>S228</lpage><pub-id pub-id-type="pmid">15118522</pub-id><pub-id pub-id-type="doi">10.1097/01.CCM.0000126120.49367.AC</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bernard</surname><given-names>GR</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name><name><surname>Laterre</surname><given-names>PF</given-names></name><name><surname>Larosa</surname><given-names>SP</given-names></name><name><surname>Dhainaut</surname><given-names>JF</given-names></name><name><surname>Lopez-Rodriguez</surname><given-names>A</given-names></name><name><surname>Steingrub</surname><given-names>JS</given-names></name><name><surname>Garber</surname><given-names>GE</given-names></name><name><surname>Helterbrand</surname><given-names>JD</given-names></name><name><surname>Ely</surname><given-names>EW</given-names></name><name><surname>Fisher</surname><given-names>CJ</given-names><suffix>Jr</suffix></name><collab>for the PROWESS Study Group</collab></person-group><article-title>Recombinant human protein. Efficacy and safety of recombinant human activated protein C for severe sepsis</article-title><source>N Engl J Med</source><year>2001</year><volume>344</volume><fpage>699</fpage><lpage>709</lpage><pub-id pub-id-type="pmid">11236773</pub-id><pub-id pub-id-type="doi">10.1056/NEJM200103083441001</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dhainaut</surname><given-names>JF</given-names></name><name><surname>Yan</surname><given-names>SB</given-names></name><name><surname>Margolis</surname><given-names>BD</given-names></name><name><surname>Lorente</surname><given-names>JA</given-names></name><name><surname>Russell</surname><given-names>JA</given-names></name><name><surname>Freebairn</surname><given-names>RC</given-names></name><name><surname>Spapen</surname><given-names>HD</given-names></name><name><surname>Riess</surname><given-names>H</given-names></name><name><surname>Basson</surname><given-names>B</given-names></name><name><surname>Johnson</surname><given-names>G</given-names><suffix>III</suffix></name><collab>PROWESS Sepsis Study Group</collab><etal></etal></person-group><article-title>Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis [see comment]</article-title><source>Thromb Haemost</source><year>2003</year><volume>90</volume><fpage>642</fpage><lpage>653</lpage><pub-id pub-id-type="pmid">14515185</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ely</surname><given-names>EW</given-names></name><name><surname>Laterre</surname><given-names>PF</given-names></name><name><surname>Angus</surname><given-names>DC</given-names></name><name><surname>Helterbrand</surname><given-names>JD</given-names></name><name><surname>Levy</surname><given-names>H</given-names></name><name><surname>Dhainaut</surname><given-names>JF</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name><name><surname>Macias</surname><given-names>WL</given-names></name><name><surname>Bernard</surname><given-names>GR</given-names></name><collab>for the PROWESS investigators</collab></person-group><article-title>Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis</article-title><source>Crit Care Med</source><year>2003</year><volume>31</volume><fpage>12</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">12544987</pub-id><pub-id pub-id-type="doi">10.1097/00003246-200301000-00002</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>S</given-names></name><name><surname>Akpom</surname><given-names>CA</given-names></name></person-group><article-title>A measure of primary sociobiological functions</article-title><source>Int J Health Serv</source><year>1976</year><volume>6</volume><fpage>493</fpage><lpage>508</lpage><pub-id pub-id-type="pmid">133997</pub-id></citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Tables</title><fig position="float" id="F1"><label>Figure 1</label><caption><p>PROWESS 28-day placebo mortality rates: effect of baseline protein C class. Placebo patient baseline and day 1 protein C levels were assessed and patient outcomes at 28 days determined. Twenty eight-day mortalities, based on baseline protein C and day 1 protein C levels are presented. Mortality of severely deficient patients at baseline increased if protein C levels remained ≤ 40% and decreased if protein C levels increased to &gt;40%. Mortality of deficient (41–80%) and normal (&gt;80%) patients increased if there was a ≥ 10% drop in protein C levels and decreased if there was no drop ≥ 10%. The area/% above the dashed lines in all baseline bar graphs represent patients that died before a day 1 protein C measurement was performed.</p></caption><graphic xlink:href="cc4946-1"></graphic></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p>PROWESS 28-day survival curves based on baseline and day 1 protein C activity levels. Baseline and day 1 protein C levels for patients by treatment group were assessed and 28-day outcomes determined. Kaplan-Meier survival curves of each group are presented. Curves were compared using the log-rank test and <italic>P </italic>&lt; 0.05 was considered significant. Severely deficient (≤ 40%), moderately deficient (41–80%) and normal (&gt;80%) baseline protein C categories are presented from left to right. <bold>(a) </bold>Survival curves of placebo patients. In all cases, if day 1 protein C levels improved (to &gt;40%) or remained stable (no ≥ 10% decrease), survival was higher than if protein C levels remained ≤ 40% or decreased by ≥ 10%. The improvement was significant only for severely deficient and deficient patients.<bold>(b) </bold>Survival curves of PROWESS drotrecogin alfa (activated) (DrotAA) patients. A similar pattern was observed in DrotAA-treated patients as in placebo patients. In all cases, 28-day survival was higher if day 1 protein C levels improved (to &gt;40%) or remained stable than if they remained ≤ 40% or decreased by ≥ 10%. The improvement was significant only for severely deficient and deficient patients.</p></caption><graphic xlink:href="cc4946-2"></graphic></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Baseline characteristics and 28-day mortality of PROWESS patients by baseline protein C level and treatment group</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Parameter</td><td align="left" colspan="2">Baseline protein C ≤ 40% of normal</td><td align="left" colspan="2">Baseline protein C 41–80% of normal</td><td align="left" colspan="2">Baseline protein C &gt;80% of normal</td></tr><tr><td></td><td colspan="6"><hr></hr></td></tr><tr><td></td><td align="left">Placebo (<italic>n </italic>= 285)</td><td align="left">DrotAA (<italic>n </italic>= 330)</td><td align="left">Placebo (<italic>n </italic>= 385)</td><td align="left">DrotAA (<italic>n </italic>= 379)</td><td align="left">Placebo (<italic>n </italic>= 105)</td><td align="left">DrotAA (<italic>n </italic>= 90)</td></tr></thead><tbody><tr><td align="left">APACHE II score*</td><td align="center">26.1 ± 8.1</td><td align="center">25.6 ± 7.7</td><td align="center">24.3 ± 7.8</td><td align="center">23.9 ± 7.5</td><td align="center">23.9 ± 7.3</td><td align="center">23.8 ± 6.7</td></tr><tr><td align="left">Age (years)</td><td align="center">61.4 ± 16.9</td><td align="center">60.9 ± 17.1</td><td align="center">60.0 ± 16.7</td><td align="center">59.9 ± 17.8</td><td align="center">61.9 ± 14.6</td><td align="center">61.4 ± 16.4</td></tr><tr><td align="left">Log IL-6*</td><td align="center">7.4 ± 2.1</td><td align="center">7.5 ± 2.2</td><td align="center">6.1 ± 2.0</td><td align="center">6.2 ± 2.0</td><td align="center">4.7 ± 1.8</td><td align="center">4.7 ± 1.7</td></tr><tr><td align="left">Urosepsis (%)</td><td align="center">9.8</td><td align="center">10.3</td><td align="center">12.2</td><td align="center">8.7</td><td align="center">3.8</td><td align="center">14.4</td></tr><tr><td align="left">Comorbidites<sup>a </sup>(%)**</td><td align="center">16.5</td><td align="center">15.5</td><td align="center">20.0</td><td align="center">19.8</td><td align="center">35.2</td><td align="center">34.4</td></tr><tr><td align="left">Dependencies<sup>b </sup>(%)**</td><td align="center">25.3</td><td align="center">21.8</td><td align="center">29.6</td><td align="center">29.3</td><td align="center">38.1</td><td align="center">33.3</td></tr><tr><td align="left">Septic shock (%)**</td><td align="center">76.8</td><td align="center">80.6</td><td align="center">72.2</td><td align="center">66.0</td><td align="center">59.0</td><td align="center">55.6</td></tr><tr><td align="left">28-day mortality (%)</td><td align="center">41.8</td><td align="center">27.6</td><td align="center">24.9</td><td align="center">24.0</td><td align="center">26.7</td><td align="center">15.6</td></tr></tbody></table><table-wrap-foot><p>DrotAA, drotrecogin alfa (activated). Patients were prospectively categorized on the basis of their baseline protein C activity levels (normal, &gt;80%; deficient, 41–80% of normal; and severely deficient, ≤ 40% of normal). <sup>a</sup>Any chronic health points from the (APACHE) II classification system. <sup>b</sup>Patient considered dependent if they were dependent in one or more activities on the Activities of Daily Living scale [16]. *Significantly different between protein C classes (<italic>P </italic>&lt; 0.05) using Spearman rank-correlation with baseline protein C levels. **Significant (<italic>P </italic>&lt; 0.05) association with baseline protein C levels using Wilcoxon rank-sum tests comparing the "yes" versus "no" classifications</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Protein C and additional measures as risk factors in PROWESS placebo patients</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Parameter</td><td align="left" colspan="3">Baseline protein C</td><td align="left" colspan="3">Baseline and day 1 protein C</td></tr><tr><td></td><td colspan="6"><hr></hr></td></tr><tr><td></td><td align="left">Odds ratio<sup>a</sup></td><td align="left">95% confidence interval</td><td align="left"><italic>P </italic>value</td><td align="left">Odds ratio<sup>a</sup></td><td align="left">95% confidence interval</td><td align="left"><italic>P </italic>value</td></tr></thead><tbody><tr><td align="left">APACHE II score<sup>b</sup></td><td align="center">1.31</td><td align="center">1.16–1.48</td><td align="center">&lt;0.0001</td><td align="center">1.33</td><td align="center">1.17–1.51</td><td align="center">&lt;0.0001</td></tr><tr><td align="left">Age<sup>c</sup></td><td align="center">1.17</td><td align="center">1.10–1.24</td><td align="center">&lt;0.0001</td><td align="center">1.17</td><td align="center">1.10–1.24</td><td align="center">&lt;0.0001</td></tr><tr><td align="left">Log IL-6<sup>d</sup></td><td align="center">1.48</td><td align="center">1.22–1.80</td><td align="center">&lt;0.0001</td><td align="center">1.30</td><td align="center">1.06–1.60</td><td align="center">0.010</td></tr><tr><td align="left">Comorbidity</td><td align="center">2.00</td><td align="center">1.32–3.03</td><td align="center">0.001</td><td align="center">1.80</td><td align="center">1.17–2.78</td><td align="center">0.008</td></tr><tr><td align="left">Dependencies<sup>e</sup></td><td align="center">1.70</td><td align="center">1.17–2.46</td><td align="center">0.006</td><td align="center">1.81</td><td align="center">1.23–2.68</td><td align="center">0.003</td></tr><tr><td align="left">Urosepsis</td><td align="center">0.47</td><td align="center">0.25–0.87</td><td align="center">0.020</td><td align="center">0.42</td><td align="center">0.22–0.79</td><td align="center">0.008</td></tr><tr><td align="left">Baseline protein C ≤ 40%</td><td align="center">1.75</td><td align="center">1.21–2.53</td><td align="center">0.003</td><td align="center">2.74</td><td align="center">1.75–4.30</td><td align="center">&lt;0.0001</td></tr><tr><td align="left">Baseline protein C ≤ 40% and day 1 protein C &gt;40%</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">0.43</td><td align="center">0.20–0.93</td><td align="center">0.030</td></tr><tr><td align="left">Baseline protein C &gt;40% and day 1 protein C 10% decrease</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">1.87</td><td align="center">1.12–3.11</td><td align="center">0.020</td></tr></tbody></table><table-wrap-foot><p>APACHE, Acute Physiology and Chronic Health Evaluation. All patients with baseline protein C values from the PROWESS trial (<italic>n </italic>= 1574) were included in analyses. Risk factors used were previously found to be significant predictors of outcome in analyses of data from PROWESS [15]. <sup>a</sup>Based on multivariable logistic regression; values &gt;1 indicate increased risk, values &lt;1 indicate lower risk. <sup>b</sup>Per 5-point increase in baseline score. <sup>c</sup>Per 5-year increase in age. <sup>d</sup>Per 10 times increase in baseline IL-6. <sup>e</sup>Patient was considered dependent if they were dependent in one or more activities on the Activities of Daily Living scale [16].</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Baseline and Day 1 protein C activity: effect of drotrecogin alfa (activated) (DrotAA) and proportion of patients that improved or worsened by baseline protein C class</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Parameter</td><td align="center" colspan="3">Treatment group</td></tr><tr><td></td><td colspan="3"><hr></hr></td></tr><tr><td></td><td align="center">Placebo (<italic>n </italic>= 709)</td><td align="center">DrotAA (<italic>n </italic>= 743)</td><td align="center"><italic>P </italic>value</td></tr></thead><tbody><tr><td align="left" colspan="4">Protein C activity<sup>a</sup></td></tr><tr><td align="left"> Baseline</td><td align="center">50% (34, 68)</td><td align="center">47% (31, 64)</td><td align="center">0.06</td></tr><tr><td align="left"> Day 1</td><td align="center">47% (30, 72)</td><td align="center">52% (36, 72)</td><td align="center">0.008</td></tr><tr><td align="left"> Day 1 change</td><td align="center">0% (-10, 9)</td><td align="center">6% (-4, 16)</td><td align="center">&lt;0.0001</td></tr><tr><td align="left" colspan="4">Proportion of patients improved or worsened (% of patients)<sup>b</sup></td></tr><tr><td align="left"> Baseline protein C ≤ 40% and day 1 protein C &gt;40%</td><td align="center">19.4</td><td align="center">35.5</td><td align="center">&lt;0.0001</td></tr><tr><td align="left"> Baseline protein C 40–80% and day 1 protein C decreased ≥ 10%</td><td align="center">29.6</td><td align="center">17.6</td><td align="center">0.0002</td></tr><tr><td align="left"> Baseline protein C &gt;80% and day 1 protein C decreased ≥ 10%</td><td align="center">30.6</td><td align="center">19.8</td><td align="center">0.09</td></tr></tbody></table><table-wrap-foot><p><bold>[AU Query: Delete any previous text that is a repeat of information in main body of article] </bold><sup>a</sup>Summary statistics reported as the median (25th percentile, 75th percentile), and <italic>P </italic>values from Wilcoxon rank-sum tests (<italic>P </italic>&lt; 0.05 significant). <sup>b</sup>Improved, baseline protein C ≤ 40% and day 1 protein C &gt;40%; Worsened, baseline protein C 41–80% or &gt;80% and a day 1 decrease in protein C ≥ 10%.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Baseline and day 1 values for protein S, antithrombin III, and IL-6 by treatment group in the PROWESS trial</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Parameter</td><td align="center" colspan="3">Treatment <bold>g</bold>roup</td></tr><tr><td></td><td colspan="3"><hr></hr></td></tr><tr><td></td><td align="center">Placebo (<italic>n </italic>= 709)</td><td align="center">Drotrecogin alfa (activated) (<italic>n </italic>= 743)</td><td align="center"><italic>P </italic>value</td></tr></thead><tbody><tr><td align="left" colspan="4">Protein S activity</td></tr><tr><td align="left"> Baseline</td><td align="center">39% (24, 59)</td><td align="center">35% (22, 57)</td><td align="center">0.09</td></tr><tr><td align="left"> Day 1</td><td align="center">36% (23, 57)</td><td align="center">35% (22, 56)</td><td align="center">0.41</td></tr><tr><td align="left"> Day 1 change</td><td align="center">0% (-9, 7)</td><td align="center">0% (-10, 9)</td><td align="center">0.59</td></tr><tr><td align="left" colspan="4">Antithrombin III</td></tr><tr><td align="left"> Baseline</td><td align="center">60% (45, 75)</td><td align="center">59% (44, 75)</td><td align="center">0.50</td></tr><tr><td align="left"> Day 1</td><td align="center">59% (45, 75)</td><td align="center">59% (44, 76)</td><td align="center">0.61</td></tr><tr><td align="left"> Day 1 change</td><td align="center">0% (-10, 9)</td><td align="center">0% (-8, 7)</td><td align="center">0.88</td></tr><tr><td align="left" colspan="4">IL-6</td></tr><tr><td align="left"> Baseline</td><td align="center">436 (126, 2338)</td><td align="center">523 (156, 2701)</td><td align="center">0.08</td></tr><tr><td align="left"> Day 1</td><td align="center">199 (68, 717)</td><td align="center">211 (77, 685)</td><td align="center">0.44</td></tr><tr><td align="left"> Day 1 change</td><td align="center">-157 (-1073, -6)</td><td align="center">-225 (-1922, -27)</td><td align="center">0.006</td></tr></tbody></table><table-wrap-foot><p>Summary statistics reported as the median (25th percentile, 75th percentile), and <italic>P </italic>values from Wilcoxon rank-sum tests (<italic>P </italic>&lt; 0.05 significant).</p></table-wrap-foot></table-wrap></sec></back></article>